Hjem
Universitetet i Bergen
Bjarne Robberstads bilde

Bjarne Robberstad

Instituttleder, Fagområde for etikk og helseøkonomi (ETØK)
Institutt for global helse og samfunnsmedisin
linkedin
  • E-postbjarne.robberstad@uib.no
  • Telefon+47 55 58 64 79+47 932 88 039
  • Besøksadresse
    Alrek helseklynge, blokk D, Årstadveien 17
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Økonomisk evaluering av helseintervensjonar

Vitenskapelig artikkel
  • Vis forfatter(e) (2022). Visiting crowded places during the COVID-19 pandemic. A panel study among adult Norwegians. Frontiers in Public Health. 17 sider.
  • Vis forfatter(e) (2022). Public participation: healthcare rationing in the newspaper media. BMC Health Services Research.
  • Vis forfatter(e) (2022). Post-discharge morbidity and mortality in children admitted with severe anaemia and other health conditions in malaria-endemic settings in Africa: a systematic review and meta-analysis. The Lancet Child and Adolescent Health. 474-483.
  • Vis forfatter(e) (2022). Economic evaluation of postdischarge malaria chemoprevention in preschool children treated for severe anaemia in Malawi, Kenya, and Uganda: A cost-effectiveness analysis. EClinicalMedicine. 1-13.
  • Vis forfatter(e) (2022). Cost-Effectiveness of Mobile Stroke Unit Care in Norway. Stroke. 3173-3181.
  • Vis forfatter(e) (2022). Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions. JAMA Network Open. 9 sider.
  • Vis forfatter(e) (2021). Validity and responsiveness of EQ-5D-5L and SF-6D in patients with health complaints attributed to their amalgam fillings: a prospective cohort study of patients undergoing amalgam removal. Health and Quality of Life Outcomes. 1-12.
  • Vis forfatter(e) (2021). Protocol for a multicentre, parallel-group, open-label randomised controlled trial comparing ferric carboxymaltose with the standard of care in anaemic Malawian pregnant women: the REVAMP trial. BMJ Open. 10 sider.
  • Vis forfatter(e) (2021). Implementing standard antenatal care interventions: health system cost at primary health facilities in Tanzania. Cost Effectiveness and Resource Allocation. 8 sider.
  • Vis forfatter(e) (2021). Cost-effectiveness of household contact investigation for detection of tuberculosis in Pakistan. BMJ Open. 8 sider.
  • Vis forfatter(e) (2021). Adherence to community versus facility-based delivery of monthly malaria chemoprevention with dihydroartemisinin-piperaquine for the post-discharge management of severe anemia in Malawian children: A cluster randomized trial. PLOS ONE. 1-16.
  • Vis forfatter(e) (2020). The cost-effectiveness of using results-based financing to reduce maternal and perinatal mortality in Malawi. BMJ Global Health.
  • Vis forfatter(e) (2020). Should we discount future health benefits? Pro et contra (English translation) . Norsk Filosofisk tidsskrift. 1-28.
  • Vis forfatter(e) (2020). Reporting of health equity considerations in cluster and individually randomized trials. Trials. 12 sider.
  • Vis forfatter(e) (2020). Poor self-reported adherence to COVID-19-related quarantine/isolation requests, Norway, April to July 2020. Eurosurveillance. 1-6.
  • Vis forfatter(e) (2020). Malaria Chemoprevention in the Postdischarge Management of Severe Anemia. New England Journal of Medicine. 2242-2254.
  • Vis forfatter(e) (2020). Bør vi diskontere fremtidige helsegevinster? Pro et contra . Norsk Filosofisk tidsskrift. 170-184.
  • Vis forfatter(e) (2019). The cost-effectiveness of incentive-based active case finding for tuberculosis (TB) control in the private sector Karachi, Pakistan. BMC Health Services Research.
  • Vis forfatter(e) (2019). Taking an integrated knowledge translation approach in research to develop the CONSORT-Equity 2017 reporting guideline: an observational study. BMJ Open. 11 sider.
  • Vis forfatter(e) (2019). Malariaprofylakse til barn med alvorlig anemi redder liv – men hva er den beste leveringsmetoden på landsbygda i Malawi? Best Practice. 20-24.
  • Vis forfatter(e) (2019). Long-lasting insecticidal nets and indoor residual spraying may not be sufficient to eliminate malaria in a low malaria incidence area: Results from a cluster randomized controlled trial in Ethiopia. Malaria Journal. 1-15.
  • Vis forfatter(e) (2018). Who benefits from increased service utilisation? Examining the distributional effects of payment for performance in Tanzania. International Journal for Equity in Health. 1-16.
  • Vis forfatter(e) (2018). Post-discharge malaria chemoprevention (PMC) in Malawi: caregivers` acceptance and preferences with regard to delivery methods methods. BMC Health Services Research. 1-11.
  • Vis forfatter(e) (2018). Malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: Study protocol for a multi-centre, two-arm, randomised, placebo-controlled, superiority trial. Trials.
  • Vis forfatter(e) (2018). Introducing post-discharge malaria chemoprevention (PMC) for management of severe anemia in Malawian children: a qualitative study of community health workers’ perceptions and motivation. BMC Health Services Research. 1-15.
  • Vis forfatter(e) (2018). Does payment for performance increase performance inequalities across health providers? A case study of Tanzania. Health Policy and Planning. 1026-1036.
  • Vis forfatter(e) (2018). Delivery strategies for malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years old in Malawi: a protocol for a cluster randomized trial. BMC Pediatrics. 1-8.
  • Vis forfatter(e) (2018). Cost-effectiveness of a combined intervention of long lasting insecticidal nets and indoor residual spraying compared with each intervention alone for malaria prevention in Ethiopia. Cost Effectiveness and Resource Allocation. 1-17.
  • Vis forfatter(e) (2017). When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework. BMJ Open. 9 sider.
  • Vis forfatter(e) (2017). Household costs and time to seek care for pregnancy related complications: The role of results-based financing. PLOS ONE. 18 sider.
  • Vis forfatter(e) (2017). Health Shocks and Household Welfare in Zambia: An Assessment of Changing Risk. Journal of International Development. 790-817.
  • Vis forfatter(e) (2017). Explaining changes in child health inequality in the run up to the 2015 millennium development goals (MDGs): The case of Zambia. PLOS ONE. 1-21.
  • Vis forfatter(e) (2017). Economic burden of malaria and predictors of cost variability to rural households in southcentral Ethiopia. PLOS ONE. 16 sider.
  • Vis forfatter(e) (2017). Early versus late BCG vaccination in HIV-1-exposed infants in Uganda: Study protocol for a randomized controlled trial. Trials. 1-17.
  • Vis forfatter(e) (2017). Does Free Public Health Care Increase Utilization and Reduce Spending? Heterogeneity and Long-Term Effects. World Development. 334-350.
  • Vis forfatter(e) (2017). Cost-effectiveness analysis of population-based tobacco control strategies in the prevention of cardiovascular diseases in Tanzania. PLOS ONE. 1-20.
  • Vis forfatter(e) (2017). Cost-benefit and extended cost-effectiveness analysis of a comprehensive adolescent pregnancy prevention program in Zambia: study protocol for a cluster randomized controlled trial. Trials. 1-10.
  • Vis forfatter(e) (2016). Malaria incidence and entomological findings in an area targeted for a cluster-randomized controlled trial to prevent malaria in Ethiopia: Results from a pilot study. Malaria Journal. 13 sider.
  • Vis forfatter(e) (2016). Equity in long-lasting insecticidal nets and indoor residual spraying for malaria prevention in a rural South Central Ethiopia. Malaria Journal. 11 sider.
  • Vis forfatter(e) (2016). Equity impact analysis of medical approaches to cardiovascular diseases prevention in Tanzania. Social Science and Medicine. 208-217.
  • Vis forfatter(e) (2016). Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: A Markov modelling study. BMC Health Services Research.
  • Vis forfatter(e) (2016). Combining long-lasting insecticidal nets and indoor residual spraying for malaria prevention in Ethiopia: Study protocol for a cluster randomized controlled trial. Trials.
  • Vis forfatter(e) (2016). Budget impact analysis of using dihydroartemisinin–piperaquine to treat uncomplicated malaria in children in Tanzania. PharmacoEconomics (Auckland). 303-314.
  • Vis forfatter(e) (2015). Factors associated with delivery outside a health facility: Cross-sectional study in rural Malawi. Tropical medicine & international health. 617-626.
  • Vis forfatter(e) (2015). Economic cost of primary prevention of cardiovascular diseases in Tanzania. Health Policy and Planning. 875-884.
  • Vis forfatter(e) (2015). Cost-effectiveness of peer counselling for the promotion of exclusive breastfeeding in Uganda. PLOS ONE. 18 sider.
  • Vis forfatter(e) (2015). Cost-effectiveness of live oral attenuated human rotavirus vaccine in Tanzania. Cost Effectiveness and Resource Allocation. 1-12.
  • Vis forfatter(e) (2014). The role of evidence in the decision-making process of selecting essential medicines in developing countries: the case of Tanzania. PLOS ONE. 10 sider.
  • Vis forfatter(e) (2014). Maternal and perinatal mortality by place of delivery in sub-Saharan Africa: A meta-analysis of population-based cohort studies. BMC Public Health.
  • Vis forfatter(e) (2014). Costs of promoting exclusive breastfeeding at community level in three sites in South Africa. PLOS ONE. 9 sider.
  • Vis forfatter(e) (2014). Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malaria Journal.
  • Vis forfatter(e) (2013). Role of pharmacoeconomics in developing countries. Farmeconomia. Health economics and therapeutic pathways. 3-5.
  • Vis forfatter(e) (2013). Infant feeding survival and Markov transition probabilities among children under age 6 months in Uganda. American Journal of Epidemiology. 453-462.
  • Vis forfatter(e) (2011). Incorporating concerns for equal lifetime health in evaluations of public health programs. Social Science and Medicine. 1711-1716.
  • Vis forfatter(e) (2011). Explaining household socio-economic related child health inequalities using multiple methods in three diverse settings in South Africa. International Journal for Equity in Health. 14 sider.
  • Vis forfatter(e) (2011). Economic evaluation of second generation pneumococcal vaccines in Norway. Vaccine. 8564-8574.
  • Vis forfatter(e) (2011). Cost of individual peer counselling for the promotion of exclusive breastfeeding in Uganda. Cost Effectiveness and Resource Allocation. 9 sider.
  • Vis forfatter(e) (2010). The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study. Cost Effectiveness and Resource Allocation.
  • Vis forfatter(e) (2010). Preventing Mother to Child Transmission of HIV With Highly Active Antiretroviral Treatment in Tanzania-a Prospective Cost-Effectiveness Study. Journal of Acquired Immune Deficiency Syndromes. 397-403.
  • Vis forfatter(e) (2010). Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy. AIDS research and therapy.
  • Vis forfatter(e) (2009). Estimating average inpatient and outpatient costs and childhood pneumonia and diarrhoea treatment costs in an urban health centre in Zambia. Cost Effectiveness and Resource Allocation.
  • Vis forfatter(e) (2009). Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia. Cost Effectiveness and Resource Allocation.
  • Vis forfatter(e) (2009). Cost estimates of HIV care and treatment with and without anti-retrovira thereapy at Arba Minch Hospital in southern Ethiopia. Cost Effectiveness and Resource Allocation.
  • Vis forfatter(e) (2007). Time preferences for health in northern Tanzania - An empirical analysis of alternative discounting models. PharmacoEconomics (Auckland). 73-88.
  • Vis forfatter(e) (2007). Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country - the case of Tanzania. Cost Effectiveness and Resource Allocation.
  • Vis forfatter(e) (2005). QALYs vs DALYs vs LYs gained: What are the differences, and what difference do they make for health care priority setting. Norsk Epidemiologi. 183-191.
  • Vis forfatter(e) (2005). QALYs vs DALYs vs LYs gained. Norsk Epidemiologi. 183-191.
  • Vis forfatter(e) (2005). Estimation of private and social time preferences for health in northern Tanzania. Social Science and Medicine. 1597-1607.
  • Vis forfatter(e) (2005). Cost and cost-effectiveness of community based and health facility based directly observed treatment of tuberculosis in Dar es Salaam, Tanzania. Cost Effectiveness and Resource Allocation. 9 sider.
  • Vis forfatter(e) (2004). Cost-effectiveness of zinc as adjunct therapy for acute childhood diarrhoea in developing countries. Bulletin of the World Health Organization. 523-531.
  • Vis forfatter(e) (2003). The relationship between prevention of mother to child transmission of HIV and stakeholder decision making in Uganda: Implications for health policy. Health Policy. 199-211.
Vitenskapelig foredrag
  • Vis forfatter(e) (2021). Symposium 3: Monthly malaria chemoprevention for the post-discharge management (PMC) of severe anaemia in children - Clinical evidence, effective implementation, acceptability, epidemiological consequences, cost-effectiveness and equity impact (introduction and overview).
  • Vis forfatter(e) (2021). Epidemiological impact of PMC.
  • Vis forfatter(e) (2021). Effectiveness of community versus facility delivery of dihydroartemisinin-peraquine for post-discharge malaria chemoprevention in management of severe anaemia in Malawian children.
  • Vis forfatter(e) (2021). Cost-effectiveness of PMC.
  • Vis forfatter(e) (2021). Caregiver's acceptance and preferences with regard to delivery methods of PMC.
  • Vis forfatter(e) (2019). Efficacy and Effectiveness of Post-Discharge Malaria Chemoprophylaxis in Kenya, Uganda, and Malawi: Preliminary report .
  • Vis forfatter(e) (2018). Post-discharge risks of morbidity and mortality in children in malaria endemic settings in Africa: A systematic review and meta-analysis - Oral presentation.
  • Vis forfatter(e) (2017). Who benefits From Increased Service Utilization: Examining The Distributional Effects Of Payment For Performance in Tanzania.
  • Vis forfatter(e) (2017). Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial.
  • Vis forfatter(e) (2017). Delivery strategies of malaria chemoprevention for post-discharge management of children with severe anemia in Malawi (oral).
  • Vis forfatter(e) (2017). CPD Migori: Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial.
  • Vis forfatter(e) (2016). CPD meeting: Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial. .
  • Vis forfatter(e) (2015). Equity effects of the Pay-for-Performance scheme among health facilities in Tanzania.
  • Vis forfatter(e) (2008). Economic evaluation of health interventions - Tanzania perspectives.
  • Vis forfatter(e) (2008). Burden of disease among the poor in Tanzania. Rights, priorities and implementation.
  • Vis forfatter(e) (2007). ART in Africa does not lead to improved equity in health.
  • Vis forfatter(e) (2007). ART in Africa does not lead to improved equity in health.
  • Vis forfatter(e) (2005). Estimation of private and social time preferences for health in northern Tanzania.
  • Vis forfatter(e) (2005). Applied economic evaluations and studies on time preferences for health in Tanzania.
  • Vis forfatter(e) (2004). Førebygging av hjarte-karsjukdom i u-land - fornuftig bruk av knappe helsebudsjett i samfunn med høg forekomst av HIV-AIDS?
  • Vis forfatter(e) (2004). Cost-effectiveness in Priority Setting.
  • Vis forfatter(e) (2003). Cost-effectiveness of zinc as adjunct treatment in acute childhood diarrhea.
  • Vis forfatter(e) (2002). The relative cost-effectiveness of interventions to control HIV/AIDS in Tanzania.
  • Vis forfatter(e) (2002). The cost-effectiveness of selected interventions targeting major source of burden of disease in Tanzania.
  • Vis forfatter(e) (2002). Cost-effectiveness of interventions in management of acute childhood diarrhea.
  • Vis forfatter(e) (2002). Antiretroviral treatment in low income settings: priority setting considerations.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2020). Patient and health system costs of managing pregnancy and birth-related complications in sub-Saharan Africa: A systematic review. Health Economics Review. 1-15.
  • Vis forfatter(e) (2019). Prosigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast Cancer. Assessment of manufacturer’s submission. Folkehelseinstituttet.
  • Vis forfatter(e) (2012). Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review. BMC Medical Informatics and Decision Making. 9 sider.

Se fullstendig oversikt over publikasjoner i CRIStin.

Artiklar i fagfelleevaluerte tidsskrift

 

  1. Mazalale, J., C Kambala, S Brenner, J Chinkhumba, J Lohmann, D Mathanga, B Robberstad, AS Muula and M de Allegri (2015). Factors associated with delivery outside a health facility: cross-sectional study in rural Malawi. Trop Med Int Health 20(5): 617-626.
  2. Chola, L., LT Fadnes, IMS Engebretsen, L Nkonki, V Nankabirwa, H Sommerfelt, JK Tumwine, T Tylleskar and B Robberstad (2015). Cost-Effectiveness of Peer Counselling for the Promotion of Exclusive Breastfeeding in Uganda. PLoS One 10(11): e0142718.
  3. Mori AT, Norheim OF, Robberstad B. Budget Impact Analysis of Using Dihydroartemisinin-Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania. Pharmacoeconomics 2015.
  4. Wisloff, T. and B. Robberstad (2015). Re: Markov-modellering. Tidsskr Nor Laegeforen 135(16): 1432.
  5. B Robberstad.  Alder og alvor (Age and severity of disease). Tidsskr Nor Laegeforen. 2015 Aug 11; 1376 – 1378.
  6. Ruhago, GM, FN Ngalesoni, B Robberstad and OF Norheim. Cost-effectiveness of live oral attenuated human rotavirus vaccine in Tanzania. BMC Cost-Effectiveness and Resource Allocation 2015, 13:7. DOI: 10.1186/s12962-015-0033-0.
  7. Chinkhumba J, M Allegri, AS Muula and B Robberstad. Maternal and perinatal mortality by place of delivery in sub-Saharan Africa: a meta-analysis of population-based cohort studies. BMC Public Health 2014, 14:1014  doi:10.1186/1471-2458-14-1014.
  8. Deressa W, E Loha, M Balkew, A Desalegne, T Gari, T Gebremichael, O Kenea, D Jima, B Robberstad, HJ Overgaard and B Lindtjørn. Poster presentation: Combining long-lasting insecticidal nets and indoor residual spraying for malaria prevention in Ethiopia: study protocol for a cluster randomized controlled trial. Malaria Journal, 09/2014; 13(suppl 1): P25. DOI: 10.1186/1475-2875-13-S1-P25.
  9. Mori AT, F Ngalesoni, OF Norheim and B Robberstad. Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania. Malaria Journal, 09/2014; 13(1):363. DOI: 10.1186/1475-2875-13-363.
  10. Ngalesoni F, G Ruhago, OF Norheimand B Robberstad. Economic cost of primary prevention of cardiovascular diseases in Tanzania.  Health Policy Plan. (2014), doi: 10.1093/heapol/czu088.
  11. Nkonki LL, E Daviaud, D Jackson, L Chola, T Doherty, M Chopra and B Robberstad. Costs of Promoting Exclusive Breastfeeding at Community Level in Three Sites in South Africa. PLOS One. 2014; Vol 9 (1); e79784.
  12. Mori AT, EA Kaale, F Ngalesoni, OF Norheim and B Robberstad. The Role of Evidence in the Decision-Making Process of Selecting Essential Medicines in Developing Coutries: The Case of Tanzania. PLOS One. 2014; Vol 9 (1); e84824.
  13. B Robberstad, JE Askildsen and OF Norheim. Styrer budsjettkonsekvens norske refusjonsprioriteringar? (Are reimbursement priorities guided by budget impact?). Tidsskr Nor Laegeforen. 2013 Sep 17;133(17):1841-3. doi: 10.4045/tidsskr.13.0215.
  14. Olsen JA, Kristiansen IS, J Magnussen, OF Norheim, B Robberstad. Fagkritikkens utfordringer (The challenges of subject criticism). Tidsskr Nor Laegeforen. 2013 Mar 5;133(5):499. Doi: 10.4045/tidsskr.13.0174.
  15. AT Mori, P Gavaza and B Robberstad.  Role of pharmacoeconomics in developing countries. Editorial. Farmeconomia. Health economics and therapeutic pathways 2013; 14(1)
  16. B Robberstad, Akselsen PE, Kværner KJ and Berstad A. Response to Reply to Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Letter. Vaccine. 2013 Jan 7;31(3):442-3.
  17. Chola L, LT Fadnes, IMS Engebretsen, T Tylleskar and B Robberstad. Infant feeding survival and Markov transition probabilities among children 0–6 months in Uganda. American Journal of Epidemiology. February 2013, DOI: 10.1093/aje/kws254.
  18. Mori AT and B Robberstad.  Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review. BMC Medical Informatics and Decision Making. 2012;12: 110.
  19. Robberstad B, CR Frostad, PE Akselsen, Kari J Kværner and Aud KH Berstad.  Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.  Vaccine 29 (2011): 8564-8574.
  20. Chola L, L Nkonki, C Kankasa, J Nankunda, J Tumwine, T Tylleskar, B Robberstad, for the PROMISE-EBF Study Group. Cost of individual peer counselling for the promotion of exclusive breastfeeding in Uganda and Zambia.  Cost Effectiveness and Resource Allocation 2011, 9:11.
  21. Robberstad B and OF Norheim.  Incorporating concerns for equal lifetime health in evaluations of public health programs.  Social Science & Medicine, Volume 72, Issue 10, May 2011, Pages 1711-1716.
  22. Nkonki LL, M Chopra, T Doherty, D Jackson, B Robberstad. Explaining household socio economic-related child health inequalities using multiple methods in three diverse settings in South Africa.  International Journal for Equity in Health, April 2011.
  23. Robberstad B and BE Olsen. Cost-effectiveness of prevention of mother to child transmission of HIV (PMTCTplus) at Haydom Hospital in Tanzania – a prospective cost-effectiveness study. J Acquir Immune Defic Syndr. Aug 24 2010.
  24. Robberstad B and JA Olsen (2010). The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa - a literature review and focus group study. Cost Eff Resour Alloc 8: 5 (11 p).
  25. Johansson, K A, B Robberstad and OF Norheim. (2010). "Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy." AIDS Research and Therapy 7(1): 3 (9 p).
  26. Chola L and Robberstad B. Estimating average inpatient and outpatient costs and childhood pneumonia and diarrhoea treatment costs in an urban health centre in Zambia. Cost Effectiveness and Resource Allocation, 2009, 7:16 (8p).
  27. Bikilla AD, D Jerene, B Robberstad and B Lindtjørn. Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia. Cost Effectiveness and Resource Allocation, 2009, 7:13 (11p).
  28. Bikilla AD, D Jerene, B Robberstad and B Lindtjørn. Cost estimates of HIV care and treatment with and without anti-retrovira thereapy at Arba Minch Hospital in southern Ethiopia. Cost Effectiveness and Resource Allocation, 2009, 7:6 (7p).
  29. Robberstad B, Y Hemed, and OF Norheim. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country - the case of Tanzania. Cost Effectiveness and Resource Allocation, 2007. 5: p. 3 (13p).
  30. Robberstad B and Cairns J. Time preferences for health in northern Tanzania : an empirical analysis of alternative discounting models. Pharmacoeconomics, 2007. 25(1): p. 73-88.
  31. Robberstad B. QALYs vs DALYs vs LYs gained:  What are the differences, and what difference do they make for health care priority setting?  Norwegian Epidemiology 2005; 15 (2): 183-191.
  32. Wandwalo E, B Robberstad, O Morkve. Cost and cost-effectiveness of community based and health facility based directly observed treatment of tuberculosis in Dar es Salaam, Tanzania. Cost Effectiveness and Resource Allocation 2005;3:6. 
  33. Robberstad B. Estimation of private and social time preferences for health in northern Tanzania.Social Science and Medicine 2005; 61(7):1597-607.
  34. Robberstad B, T Strand, RE Black, H Sommerfelt. Cost-effectiveness of zinc as adjunct therapy for acute childhood diarrhoea in developing countries. Bulletin of the World Health Organization 2004;82(7):523-31.
  35. Kapiriri L, B Robberstad and OF Norheim.  The Relationship between prevention of Mother to Child Transmission of HIV and Stakeholder Decision Making in Uganda:  Implications for Health Policy.  Health Policy, 66, 199-211, 2003.

 

 

 

                                             

Bøker og bokkapittel    

        

 

  1. Jan vd Broeck, J Brestoff, C Kaulfuss and B Robberstad. Statistical Modeling (40 pages). In: Jan vd Broeck and Jonathan Brestoff (eds). Epidemiology – Principles and practical guidelines. Springer Verlag; DOI 10.1007/978-94-007-5989-3_10.
  2. Jan vd Broeck, J Brestoff, A Friedman, N Becker, M Hoaglin and B Robberstad. The measurement plan (43 pages). In: Jan vd Broeck and Jonathan Brestoff (eds). Epidemiology – Principles and practical guidelines. Springer Verlag; DOI 10.1007/978-94-007-5989-3_10.
  3. Sanders D, B Hutton, T Njamhanga, K Heggenhougen, G Kvåle and B Robberstad (editors). Globalization and Health. Copyright © 2012, University of the Western Cape, University of Bergen, Muhimbili University of Health and Allied Sciences.
  4. Robberstad B andY Hemed: Economic Evaluation of Health Interventions: Tanzania Perspectives. In Handbook of Disease Burden. Edited by Preedy VA. Heidelberg: Springer Verlag; 2009:547-586.
  5. B Robberstad: Economic evaluation of health interventions in sub-Saharan Africa. Applied economic evaluations and studies on time preferences for health in Tanzania. Thesis, submitted to University of Bergen, 2005.

 

 

 

 

 

 

 

1. Malaria Chemoprevention for the post-discharge management of severe anaemia in children in Malawi, Uganda and Kenya (IPTpd): Moving towards policy.  Budget 32.8 mill NOK, Research council of Norway, 2014-2019

PhD Social Economics

Title of dissertation: Economic evaluation of health interventions in sub-Saharan Africa. Applied economic evaluations and studies on time preferences for health in Tanzania. Dissertation for the PhD degree. University of Bergen 2005.

MSc Developing Economics

Title of thesis: Time Toil and Soil - Time preferences and soil conservation practices in northern Tanzania. Norwegian University of Life Sciences 1997.

Kompetansefelt 
Globale helseprioriteringer

Twitter